STOCK TITAN

Taysha Gene Therapies: RA Capital reports 9.99% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Taysha Gene Therapies, Inc. (TSHA) is the subject of an amended ownership report in which RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah each report beneficial ownership of 32,785,574 shares as of September 30, 2026, with shared voting and dispositive power. RA Capital is the Fund’s investment adviser; Kolchinsky and Shah are controlling persons of RA Capital’s general partner.

The Fund directly holds 30,435,190 common shares and pre-funded warrants exercisable for up to 52,134,718 shares. A 9.99% beneficial-ownership blocker restricts exercise when the Fund, its affiliates and attribution parties would exceed that threshold; the Fund is currently barred from exercising a portion of the warrants that would result in beneficial ownership above 32,785,574 shares. The reported 9.99% ownership percentage is based on 325,833,545 shares outstanding as of August 11, 2026, giving effect to warrants exercisable within 60 days.

Beneficial ownership 32,785,574 shares Each of the four reporting persons reported this amount as of September 30, 2026.
Beneficial ownership percentage 9.99% Reported as of September 30, 2026; based on 325,833,545 shares outstanding as of August 11, 2026, giving effect to warrants exercisable within 60 days.
Fund common shares held directly 30,435,190 shares Common shares held directly by RA Capital Healthcare Fund, L.P.
Pre-funded warrant share amount Up to 52,134,718 shares Shares issuable upon exercise of pre-funded warrants held by the Fund, subject to the beneficial-ownership blocker.
Common shares outstanding 325,833,545 shares Outstanding as of August 11, 2026.
Cover-page percentage 9.9% Rounded down from 9.99% due to EDGAR filing-system field limitations.
Pre-Funded Warrants financial
"Pre-Funded Warrants exercisable for up to 52,134,718 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Beneficial Ownership Blocker regulatory
"the Beneficial Ownership Blocker precludes exercise"
A beneficial ownership blocker is a legal or structural device that prevents a shareholder from being treated as the ultimate owner of enough shares to trigger control, reporting, or voting thresholds. Think of it like a speed bump that stops an investor from reaching a stake size that would force corporate disclosure or change control rights. Investors care because it affects who controls the company, how shares vote, regulatory filings, takeover risk and therefore potential value or liquidity of their holdings.
shared dispositive power regulatory
"Shared Dispositive Power 32,785,574.00"
attribution parties regulatory
"affiliates and other attribution parties"
Section 13(d) regulatory
"for purposes of Section 13(d) of the Act"
A Section 13(d) filing is a public disclosure required under U.S. securities law when a person or group acquires more than 5% of a company’s registered equity and may influence control. The filer must report who owns the shares, how they were acquired, and any plans or intentions for the company, so the market and other shareholders can see if a large buyer is attempting a takeover or other strategic move. Think of it like a formal announcement that someone has crossed a threshold and is showing their hand.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TSHA shares did the reporting persons beneficially own?

Each of the four reporting persons reported beneficial ownership of 32,785,574 shares as of September 30, 2026, with shared voting and dispositive power.

Why do four reporting persons report the same TSHA share amount?

The Fund delegated sole voting and dispositive power over its portfolio securities to RA Capital. RA Capital may be deemed a beneficial owner for Section 13(d) purposes, and Peter Kolchinsky and Rajeev Shah may be deemed beneficial owners as managers of RA Capital. The parties also state disclaimers of beneficial ownership.

Why does the TSHA ownership report show both 9.9% and 9.99%?

The narrative reports 9.99% beneficial ownership as of September 30, 2026. The cover-page percentage is 9.9%, rounded down due to EDGAR filing-system field limitations.

What limits exercise of the TSHA pre-funded warrants?

The blocker precludes exercise to the extent the Fund, together with its affiliates and other attribution parties, would own more than 9.99% of TSHA common stock after exercise. The Fund states it is currently prohibited from exercising a portion that would result in beneficial ownership above 32,785,574 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





877619106

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



RA Capital Management, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By Peter Kolchinsky, Authorized Signatory
Date:11/16/2026
Peter Kolchinsky
Signature:/s/ Peter Kolchinsky
Name/Title:Peter Kolchinsky
Date:11/16/2026
Rajeev Shah
Signature:/s/ Rajeev Shah
Name/Title:Rajeev Shah
Date:11/16/2026
RA Capital Healthcare Fund, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
Date:11/16/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 1 to the Reporting Persons' Schedule 13G/A filed with the SEC on November 14, 2024).

Keep reading